Loading clinical trials...
Loading clinical trials...
A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension
Conditions
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
Brinzolamide ophthalmic suspension, 1%
+1 more
Start Date
March 1, 2011
Primary Completion Date
June 1, 2012
Completion Date
June 1, 2012
Last Updated
July 4, 2013
NCT07390890
NCT05902871
NCT07218796
NCT07119580
NCT06865144
NCT06689696
Lead Sponsor
Alcon Research
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions